非霍奇金淋巴瘤患者的易布鲁替尼相关尿道炎:病例报告和文献综述
Rafael Mendez1, Juan Sebastián Pineda-Sierra2, Sofia Romero-Santos2
1Ophthalmology Department, Hospital Universitario San Ignacio, Facultad de Medicina, Pontificia Universidad Javeriana, Bogota, Colombia.
Ocular immunology and inflammation
|September 24, 2024
概括
伊布鲁丁尼布可以引起眼睛炎症,一种眼睛炎症. 早期诊断和治疗,包括停止ibrutinib,对于控制这种罕见的副作用至关重要.
科学领域:
- 眼科医生 眼科 眼科
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 易布鲁替尼是布鲁顿氨酸激酶抑制剂,用于治疗B细胞恶性瘤.
- 尿道炎是一种潜在的,虽然不常见的,易布鲁替尼治疗的副作用.
- 识别与易布鲁替尼相关的脑膜炎对于及时干预至关重要.
研究的目的:
- 为了呈现两例易布鲁丁尼布诱导的脑膜炎.
- 审查关于与易布鲁替尼相关的脑膜炎的现有文献.
主要方法:
- 根据CARE指导方针进行的案例报告.
- 对以前报告的病例进行文献审查.
- 临床检查和诊断膜炎的工作.
主要成果:
- 两名患有B细胞恶性瘤的女性患者在启动ibrutinib后出现了双边卵巢炎.
- 呈现包括前端中间或面膜炎与黄斑.
- 没有发现任何二次原因;据推测,ibrutinib的毒性是病因.
结论:
- 与易布鲁替尼相关的脑膜炎是一种新出现的,经常被忽视的疾病.
- 双边的,非细粒状的前端中介性脑膜炎与斑点是常见的表现.
- 管理通常涉及局部皮质类固醇和ibrutinib的中止,并可能切换到下一代抑制剂.
相关概念视频
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...